Payment overview · 2025
General Payments
$33.37
2 reported records · 2 companies
Healthcare provider profile · identity verified
Ronald Beauzile, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BELCHERTOWN, MA · NPI 1003062647
Verified facts
What the public records show
CMS Open Payments records show Ronald Beauzile, MD received $33.37 in general payments during 2025 across 2 reported records.
Exact Sciences Corporation accounted for 59.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.76 | 59.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.61 | 40.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $33.37 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 696 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 561 | 146 |
| Lisinopril | Lisinopril | 477 | 128 |
| Omeprazole | Omeprazole | 347 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 345 | 81 |
| Gabapentin | Gabapentin | 275 | 68 |
| Metformin Hcl | Metformin Hcl | 263 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 57 |
| Furosemide | Furosemide | 205 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 173 | 36 |
| Losartan Potassium | Losartan Potassium | 159 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 40 |
| Trazodone Hcl | Trazodone Hcl | 143 | 33 |
| Allopurinol | Allopurinol | 141 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 39 |
| Eliquis | Apixaban | 134 | 28 |
| Simvastatin | Simvastatin | 132 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 36 |
| Glimepiride | Glimepiride | 123 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 38 |
| Prednisone | Prednisone | 102 | 62 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 26 |
| Atenolol | Atenolol | 96 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 95 | 26 |
| Metformin Hcl Er | Metformin Hcl | 93 | 19 |
| Ozempic | Semaglutide | 92 | 13 |
| Buspirone Hcl | Buspirone Hcl | 89 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 87 | 21 |
| Sertraline Hcl | Sertraline Hcl | 85 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 18 |
| Lorazepam | Lorazepam | 81 | 31 |
| Lamotrigine | Lamotrigine | 78 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 78 | 23 |
| Famotidine | Famotidine | 77 | 26 |
| Lovastatin | Lovastatin | 76 | 19 |
| Jardiance | Empagliflozin | 72 | 13 |
| Baclofen | Baclofen | 65 | suppressed |
| Meloxicam | Meloxicam | 65 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 63 | 15 |
| Fenofibrate | Fenofibrate,micronized | 58 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Valsartan | Valsartan | 55 | 18 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 53 | suppressed |
| Clonazepam | Clonazepam | 51 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 49 | 11 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Trulicity | Dulaglutide | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Carvedilol | Carvedilol | 41 | 12 |
| Celecoxib | Celecoxib | 41 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | 11 |
| Montelukast Sodium | Montelukast Sodium | 39 | 11 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Rybelsus | Semaglutide | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Finasteride | Finasteride | 31 | 11 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Enulose | Lactulose | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Carbamazepine Er | Carbamazepine | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Zonisamide | Zonisamide | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Digoxin | Digoxin | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Entecavir | Entecavir | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Wellbutrin Sr | Bupropion Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33.37 · 2 records | Exact Sciences Corporation | ELIQUIS, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error